ProPhase Non Operating Income Net Other from 2010 to 2024

PRPH Stock  USD 0.65  0.03  4.41%   
ProPhase Labs' Non Operating Income Net Other is increasing with slightly volatile movements from year to year. Non Operating Income Net Other is estimated to finish at about 74.9 K this year. For the period between 2010 and 2024, ProPhase Labs, Non Operating Income Net Other quarterly trend regression had mean deviation of  40,375 and range of 132 K. View All Fundamentals
 
Non Operating Income Net Other  
First Reported
2011-06-30
Previous Quarter
-96 K
Current Value
35 K
Quarterly Volatility
54.2 K
 
Yuan Drop
 
Covid
Check ProPhase Labs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ProPhase Labs' main balance sheet or income statement drivers, such as Interest Expense of 1.3 M, Selling General Administrative of 32.8 M or Total Revenue of 35.5 M, as well as many indicators such as Price To Sales Ratio of 1.66, Dividend Yield of 0.067 or PTB Ratio of 1.5. ProPhase financial statements analysis is a perfect complement when working with ProPhase Labs Valuation or Volatility modules.
  
Check out the analysis of ProPhase Labs Correlation against competitors.
For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.

Latest ProPhase Labs' Non Operating Income Net Other Growth Pattern

Below is the plot of the Non Operating Income Net Other of ProPhase Labs over the last few years. It is ProPhase Labs' Non Operating Income Net Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ProPhase Labs' overall financial position and show how it may be relating to other accounts over time.
Non Operating Income Net Other10 Years Trend
Slightly volatile
   Non Operating Income Net Other   
       Timeline  

ProPhase Non Operating Income Net Other Regression Statistics

Arithmetic Mean53,544
Geometric Mean22,978
Coefficient Of Variation91.93
Mean Deviation40,375
Median62,000
Standard Deviation49,226
Sample Variance2.4B
Range132K
R-Value0.54
Mean Square Error1.8B
R-Squared0.29
Significance0.04
Slope5,967
Total Sum of Squares33.9B

ProPhase Non Operating Income Net Other History

202474.9 K
202371.3 K
202062 K
2017133 K
2016 1000.0
2014 4000.0
2013 2000.0

About ProPhase Labs Financial Statements

Investors use fundamental indicators, such as ProPhase Labs' Non Operating Income Net Other, to determine how well the company is positioned to perform in the future. Although ProPhase Labs' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Non Operating Income Net Other71.3 K74.9 K

Currently Active Assets on Macroaxis

When determining whether ProPhase Labs offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ProPhase Labs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Prophase Labs Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Prophase Labs Stock:
Check out the analysis of ProPhase Labs Correlation against competitors.
For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.
You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProPhase Labs. If investors know ProPhase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProPhase Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.95)
Earnings Share
(1.53)
Revenue Per Share
0.996
Quarterly Revenue Growth
(0.81)
Return On Assets
(0.23)
The market value of ProPhase Labs is measured differently than its book value, which is the value of ProPhase that is recorded on the company's balance sheet. Investors also form their own opinion of ProPhase Labs' value that differs from its market value or its book value, called intrinsic value, which is ProPhase Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProPhase Labs' market value can be influenced by many factors that don't directly affect ProPhase Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProPhase Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProPhase Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProPhase Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.